Category: Covid-19 Vaccine

usatoday.com wants to ensure the best experience for all of our readers, so we built our site to take advantage of the latest technology, making it faster and easier to use.

Unfortunately, your browser is not supported. Please download one of these browsers for the best experience on usatoday.com

Follow this link:

Claim of link between mpox and COVID-19 vaccines is nonsense | Fact check - USA TODAY

A next-generation COVID-19 mucosal vaccine is set to be a gamechanger not only when delivering the vaccine itself, but also for people who are needle-phobic.

New Griffith University research, published in Nature Communications, has been testing the efficacy of delivering a COVID-19 vaccine via the nasal passages.

Professor Suresh Mahalingam from Griffith's Institute for Biomedicine and Glycomics has been working on this research for the past four years.

This is a live attenuated intranasal vaccine, called CDO-7N-1, designed to be administered intranasally, thereby inducing potential mucosal immunity as well as systemic immunity with just a single dose."

Suresh Mahalingam, Professor, Institute for Biomedicine and Glycomics, Griffith University

Mahalingam added, "The vaccine induces strong memory responses in the nasal mucosa offering long-term protection for up to a year or more.

"It's been designed to be administered as single dose, ideally as a booster vaccine, as a safe alternative to needles with no adverse reactions in the short or long term."

Live-attenuated vaccines offer several significant advantages over other vaccine approaches.

They induce potent and long-lived humoral and cellular immunity, often with just a single dose.

Live-attenuated vaccines comprise the entire virus thereby providing broad immunity, in contrast to a single antigen which is used in many other vaccine platforms.

Lead author Dr Xiang Liu said the vaccine provides cross-protection against all variants of concern, and has neutralising capacity against SARS-CoV-1.

"The vaccine offers potent protection against transmission, prevents reinfection and the spread of the virus, while also reducing the generation of new variants," Dr Liu said.

"Unlike the mRNA vaccine which targets only the spike protein, CDO-7N-1 induces immunity to all major SARS-CoV-2 proteins and is highly effective against all major variants to date.

"Importantly, the vaccine remains stable at 4C for seven months, making it ideal for low- and middle-income countries."

The vaccine has been licensed to Indian Immunologicals Ltd, a major vaccine manufacturer.

Dr. K. Anand Kumar, co-author of the publication and ManagingDirector of Indian Immunologicals Ltd. Said: "We are a leading 'One Health' company that has developed and launched several vaccines for human and animal use in India and are currently exporting to 62 countries."

"We have completed all the necessary studies of this novel COVID-19 vaccine which offers tremendous advantages over other vaccines.

"We now look forward to taking the vaccine candidate to clinicaltrials."

Professor Lee Smith, Acting Director of the Institute for Biomedicine and Glycomics, said he was delighted with the research findings.

"These results towards developing a next-generation COVID-19 vaccine are truly exciting," Professor Smith said.

"Our researchers are dedicated to providing innovative and, crucially, more accessible solutions to combat this high-impact disease."

Source:

Journal reference:

Liu, X., et. al. (2024) A single-dose intranasal live-attenuated codon deoptimized vaccine provides broad protection against SARS-CoV-2 and its variants. Nature Communications. doi.org/10.1038/s41467-024-51535-y

Read the original post:

New intranasal COVID-19 vaccine promises broad protection and accessibility - News-Medical.Net

As new, highly contagious mutations are making this summers COVID surge significantly bigger than expected, the FDA approved updated COVID vaccines on Friday. But funding runs out this month for a federal program providing free vaccines to uninsured and underinsured Americans. John Yang speaks with PBS News digital health reporter Laura Santhanam for more.

Read the original here:

What the end of a COVID vaccine access program means for uninsured Americans - PBS NewsHour

jsonline.com wants to ensure the best experience for all of our readers, so we built our site to take advantage of the latest technology, making it faster and easier to use.

Unfortunately, your browser is not supported. Please download one of these browsers for the best experience on jsonline.com

Continued here:

When and where to get the latest COVID-19 vaccines in Wisconsin - Milwaukee Journal Sentinel

Request blocked. We can't connect to the server for this app or website at this time. There might be too much traffic or a configuration error. Try again later, or contact the app or website owner. If you provide content to customers through CloudFront, you can find steps to troubleshoot and help prevent this error by reviewing the CloudFront documentation. Generated by cloudfront (CloudFront)Request ID: pRxhziwUxiOMklI7wK25-aSDk3PXN0EmFRcsHHVgukvG-v95Es_FtQ==

Follow this link:

New COVID-19 vaccine approval expected this week - NJ Spotlight News

A new, highly contagious and severe strain of mpox virus, formerly known as monkeypox, is spreading across the globe following a major outbreak in Africa.

Clade Ib, the new variant of clade I, first reported in September last year among sex workers in the mining town of Kamituga in the Democratic Republic of Congo, has now mutated, affecting children under the age of 15.

On August 14, the World Health Organization and African Center for Disease Control and Prevention (African CDC) declared mpox a global public health emergency for the second time in two years after it spread to DRC neighboring countries that had no previous record of mpox cases.

Responding to the WHO mpox global emergency declaration, Eric Amunga, commonly known as AMERIX on X, accused the WHO of being a criminal organization and asked his 1.9 million followers to shun the safety guidelines it issued:

MONKEYPOX is a scam. Don't comply. Refuse. Pfizer wants to clear its COVID-19 vaccine stocks after people shunned them. Afrika's corrupt political establishment wants to divert the boiling GenZ rebellion. Mpox is another scam by WHO crook.

That is false.

Mpox killed 517 and infected 17,000 this year alone, the African CDC reported. With new, more aggressive mutations, it has elevated to a global health crisis. COVID-19 vaccines do not apply to mpox prevention. A smallpox Jynneos vaccine, developed by the Danish company Bavarian Nordic, is used to treat the mpox virus.

The African Union (AU) Champion on Pandemic Prevention, Preparedness, and Response (PPPR), which represents the 54 African countries, said on August 16 that the number of affected African countries could rise from 13 to 16 after 3 more countries reported cases under investigation for confirmation.

Sweden reported its first case of mpox after the WHO announcement. Since then, new cases have been recorded elsewhere outside of Africa.

Since 2022, the U.S. has recorded 32,000 cases of infections and 58 deaths, mostly affecting gay and bisexual men.

Amunga did not tell his close to 2 million followers on X that mpox is not a new disease. The virus was discovered in 1958 in a colony of monkeys, and the first case of human infection was recorded in 1970 in the Democratic Republic of Congo.

According to the CDC, the virus is most common in the tropical rainforests of West and Central Africa, and thousands of cases are reported every year.

While thoroughly false, Amungas call of no compliance with the WHO mpox recommendations and his portrayal of the vaccine to prevent a severe reaction to the virus as a scam are part of a viral global trend on X, involving thousands of anti-vaxxers and reaching millions of users.

Originally posted here:

Mpox is no hoax and COVID-19 vaccine has nothing to do with it - Voice of America - VOA News

Request blocked. We can't connect to the server for this app or website at this time. There might be too much traffic or a configuration error. Try again later, or contact the app or website owner. If you provide content to customers through CloudFront, you can find steps to troubleshoot and help prevent this error by reviewing the CloudFront documentation. Generated by cloudfront (CloudFront)Request ID: ZcBGPntCkyNivWBRRiA29JveGruxxlAE1a1_8li2U2EIat8A5Zkxiw==

Originally posted here:

New COVID-19 vaccine approval expected this week - MetroFocus

IOWA CITY, Iowa Health leaders in Iowa warn that COVID-19 cases are on the rise across the state, mirroring a national trend.

Iowa Public Health no longer provides specific numbers of cases and hospitalizations. However, wastewater data and the rate of positive tests confirm that new variants are spreading rapidly.

What most folks have noticed over the past couple of weeks or month is a spike in cases once again, Sam Jarvis, with Johnson County Public Health, said.

Although many have returned to living without any precautions, the pandemic continues. While the flu is largely seasonal, spikes in COVID still happen year-round and cases continue to spread around the globe. Years of exposure and vaccination are having a positive impact.

Jarvis said 90% of the U.S. population have some level of immunity, whether from vaccination or infection.

But as time goes on, we'll continue to encourage folks to stay up to date as possible to hopefully reduce symptoms and protect them from getting infected, he said.

Public health officials are concerned as children return to school soon which could potentially increase transmission. However, not everyone is planning to get vaccinated.

Sophia Knauff, a University of Iowa freshman, expressed her doubts.

I don't think there was a lot of research done on it, she said.

Knauff, who plans to get a flu shot, has never received the COVID vaccine and doesn't plan on getting it this year.

I feel like young people like us don't really need that. But, I think definitely the people that are at risk should take all the precautions for sure," she said.

Health leaders said opinions expressing opposition to the vaccine is common.

As the effects of the pandemic fade into the background, the vaccination rate has fallen from the highs seen in 2021.

I believe it's roughly reported between the high 20% to low 40% across the board, but we'd like to see that higher, Jarvis said.

One reason for that is that new variants can evade immunity earned through infection or prior vaccination.

The Centers for Disease Control and Prevention (CDC) could approve new vaccines to protect against the latest variants as early as this week.

Manufacturers said once that happens, they can have the new shots available to the public in a matter of days.

Excerpt from:

New COVID variants fuel spike in cases as updated vaccine is on its way - KGAN TV

clarionledger.com wants to ensure the best experience for all of our readers, so we built our site to take advantage of the latest technology, making it faster and easier to use.

Unfortunately, your browser is not supported. Please download one of these browsers for the best experience on clarionledger.com

Continued here:

Curious Mississippi: Is it time to get the new COVID-19 booster? - Clarion Ledger

WASHINGTON, DC The U.S. Food and Drug Administration is set to approve the latest COVID-19 vaccines for the ongoing pandemic. CNN reports two sources familiar with the matter say approval could come before the end of next week.

The FDA will likely approve the updated mRNA vaccines from Pfizer/BioNTech and Moderna that target one of the latest strains of COVID-19 known as KP.2. Novavax's updated shot targets another strain known as JN.1.

If approved next week, it would come much earlier than last year, when updated vaccines were approved by the FDA on September 11.

The new vaccines come as a surge of COVID-19 cases have been reported in recent weeks across the country. Although detailed monitoring of cases is no longer conducted, an analysis of wastewater levels was found to be at its highest rate during the summer months since 2022.

ER visits, hospitalizations and deaths are also on the rise, with four times the rate of hospitalizations in July compared to May.

Pfizer and Moderna tell CNN they already have plenty of the updated vaccines ready to go once they receive approval, and will ship them out immediately following approval, and available in pharmacies and health care centers in a matter of days after approval.

The World Health Organization declared the Coronavirus Pandemic started in March of 2020 and has not yet ended, as cases continue to spread across every populated continent year-round, unlike more seasonsal epidemics like the flu.

See the rest here:

Updated COVID-19 vaccines could be ready next week - KGAN TV